Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Werewolf Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
HOWL
Nasdaq
2834
werewolftx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Werewolf Therapeutics, Inc.
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
- Nov 7th, 2025 7:00 am
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
- Nov 4th, 2025 5:00 am
Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake
- Oct 31st, 2025 6:58 am
Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised
- Oct 29th, 2025 11:45 am
BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy
- Oct 28th, 2025 12:26 pm
Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil
- Oct 23rd, 2025 12:54 pm
Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why
- Oct 23rd, 2025 10:00 am
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
- Oct 8th, 2025 6:00 am
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
- Oct 3rd, 2025 7:00 am
3 Promising Penny Stocks With Market Caps Under $700M
- Sep 25th, 2025 12:05 pm
Werewolf Therapeutics, Inc. (HOWL) Just Flashed Golden Cross Signal: Do You Buy?
- Sep 8th, 2025 3:03 pm
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
- Sep 2nd, 2025 6:00 am
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
- Aug 14th, 2025 5:00 am
XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates
- Aug 13th, 2025 6:55 am
Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates
- Aug 12th, 2025 3:35 pm
CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates
- Aug 7th, 2025 6:25 am
ReAlta Life Sciences Appoints Ellen Lubman as Chief Business Officer
- Jul 29th, 2025 10:30 am
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
- Jul 9th, 2025 6:00 am
Werewolf Therapeutics to Participate in the BIO International Convention
- Jun 12th, 2025 6:00 am
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
- May 29th, 2025 10:00 am
Scroll